GH — Guardant Health Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.16bn
- $2.13bn
- $563.95m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -67.9 | -246 | -385 | -655 | -479 |
Depreciation | |||||
Non-Cash Items | 15.4 | 174 | 194 | 248 | 57.8 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -6.09 | -47.7 | -40.5 | 61.6 | 53.8 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -47.1 | -104 | -209 | -309 | -325 |
Capital Expenditures | -21.2 | -54.1 | -75 | -77.5 | -20.5 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -296 | -563 | 11.9 | 227 | 861 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -318 | -617 | -63.2 | 150 | 840 |
Financing Cash Flow Items | -1.03 | -94.6 | -83.8 | -201 | -26.3 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 367 | 1,410 | -66.8 | -189 | 477 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2.68 | 690 | -341 | -350 | 992 |